Table 1.

Tumor spectrum and analysis

Tumor types BubR1K243R/+ (n = 121) BubR1+/+ (n = 41) 
Malignant tumors 28 (23.1%) 2 (4.8%) 
Malignant solid tumors 13 (10.7%) 1 (2.4%) 
Hepatocellular carcinoma 6 (5.0%)  
Sarcomaa 4 (3.3%) 1 (2.4%) 
Adenocarcinomab 2 (1.7%)  
Other cancerc 1 (0.8%)  
Hematologic malignancies 15 (12.4%) 1(2.4%) 
Megakaryocyte leukemia 1 (0.8%)  
B cell lymphoma 11 (9.1%) 1 (2.4%) 
Metastatic lymphoma/leukemia 3 (2.5%)  
Benign tumorsd 18 (14.9%)  
Total tumor incidence 46 (38.0%) 2 (4.8%) 
Tumor types BubR1K243R/+ (n = 121) BubR1+/+ (n = 41) 
Malignant tumors 28 (23.1%) 2 (4.8%) 
Malignant solid tumors 13 (10.7%) 1 (2.4%) 
Hepatocellular carcinoma 6 (5.0%)  
Sarcomaa 4 (3.3%) 1 (2.4%) 
Adenocarcinomab 2 (1.7%)  
Other cancerc 1 (0.8%)  
Hematologic malignancies 15 (12.4%) 1(2.4%) 
Megakaryocyte leukemia 1 (0.8%)  
B cell lymphoma 11 (9.1%) 1 (2.4%) 
Metastatic lymphoma/leukemia 3 (2.5%)  
Benign tumorsd 18 (14.9%)  
Total tumor incidence 46 (38.0%) 2 (4.8%) 
a

Sarcomas included smooth muscle sarcoma (n = 2), endometrial stromal sarcoma (n = 1), and angiosarcoma (n = 1) in K243R/+ mice. A single fibrosarcoma was found in the WT.

b

Adenocarcinomas included lung adenocarcinoma (n = 1) and rectal adenocarcinoma (n = 1) in K243R/+.

c

Other cancer included skin cancer.

d

Benign tumors included simple cysts in the genital tract (n = 10), hemangioma (n = 5), epidermal cyst (n = 1), acrochordon (n = 1), and mesenchymal fibroma (n = 1).

or Create an Account

Close Modal
Close Modal